Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

achieved normalization of UFC after six months without dose up-titration relative to randomized dose(1). UFC is typically used to diagnose and monitor Cushing's disease. In this test, urine is collected over 24 hours to assess average cortisol secretion(2). The primary endpoint was met for the higher dose tested (900ug sc twice daily)(1). Secondary endpoints included safety, time to response, response duration and changes from baseline in clinical signs, symptoms, tumor volume and health-related quality of life(10).

After six months, the primary efficacy responder rate was 26.3% (95% confidence interval [CI], 16.6 to 35.9) and 14.6% (95% CI, 7.0 to 22.3), respectively, for the 900ug and 600ug groups. Based on pre-specified criteria (lower bound of 95% CI >15%), the 900ug group met the primary endpoint and the 600ug group did not meet the primary endpoint. After 12 months, the proportion of responders regardless of dose up-titration was 13.4% and 25.0%, respectively, for the 600ug and 900ug groups. The median reduction in UFC after six months was 47.9% for both groups. The median reduction in UFC after 12 months was 67.6% (600ug) and 62.4% (900ug). Patients who showed little to no improvement in UFC levels (<50% reduction from baseline) by month two were unlikely to show improvement by month six or 12. The most frequently reported adverse events suspected by the investigators to be related to the study drug were diarrhea (58%), nausea (46.9%), hyperglycemia (38.9%), cholelithiasis (29.6%), abdominal pain (20.4%), diabetes mellitus (17.9%), fatigue (11.7%) and increased glycosylated hemoglobin (10.5%), with most events being Grade 1-2. Overall, the tolerability profile of SOM230 is similar to other somatostatin analogs with the exception of the greater degree of hyperglycemia, which appears manageable with early detection and appropriate intervention following established treatment guidelines. As may be expected with a treatment that lowers co
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 30, 2015 Roche (SIX: RO, ROG; ... cobas® EGFR Mutation Test v2 for Premarket Approval ... (FDA), as a companion diagnostic test for AZD9291, ... cancer patients with an acquired resistant mutation.  ... who have adenocarcinoma with tumor containing an EGFR ...
(Date:7/29/2015)... YORK, Pa. , July 29, 2015  Unilife ... and ASX: UNS), a developer, manufacturer and supplier of ... a multifaceted financing strategy that provides the Company with ... Unilife has signed an equity purchase ... Capital Fund, LLC ("LPC"), a Chicago ...
(Date:7/29/2015)... Calif. , July 29, 2015 Daiichi ... Daiichi Sankyo Group, announced today that The New ... results demonstrating that the investigational drug, PLX3397, an oral ... patients with tenosynovial giant cell tumor (TGCT), a rare, ... Following phase 1 dose-escalation, which evaluated the ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
... to Millennium Research Group (MRG), the global authority on medical ... market is largely a replacement market, there are key opportunities ... Kingdom and France. In the UK, the expected ... in 2013 presents a large opportunity for radiology PACS and ...
... Kendle (Nasdaq: KNDL ), a leading, global full-service ... the upcoming Lazard Capital Markets 7th Annual Healthcare Conference on ... New York City. Kendle,s formal presentation will be ... Senior Vice President and Chief Operating Officer and Keith Cheesman, ...
Cached Medicine Technology:European PACS Market To Attain $512M by 2015 2Kendle to Present at Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... 2015 , ... Political unrest is the number one concern ... survey by leading international insurance provider Clements Worldwide. The "Clements Worldwide Risk Index" ... largest sources of financial losses among respondents. , Twenty-eight percent of top managers ...
(Date:7/30/2015)... ... 2015 , ... HEALTHCAREfirst , the leading provider of cloud-based software, services ... hosting a free webinar detailing the 2016 proposed rule from CMS for home health. ... President of Regulatory Affairs for the National Association for Home Care and Hospice (NAHC), ...
(Date:7/30/2015)... ... July 30, 2015 , ... Case Mason ( http://www.casemason.com ... consumer brands, recently completed a consolidation of all of its production capabilities to ... out of two separate locations situated 11 miles apart. , The advantages of ...
(Date:7/29/2015)... ... 30, 2015 , ... Macro Wealth Management (MWM) Presidents have increased ... Lifetime program by encouraging their clients to donate their MWM planning fees to the ... McClellan and Tim Streid, who see charitable giving as an important part of financial ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... named Jim Bohnsack vice,president of healthcare information solutions, a ... in the Western region of the United States. , ... president of healthcare,for TransUnion. , ... relationships,with key supporting institutions and organizations will be an ...
... will see Japan,s Trinity Design Corporation Ltd, becoming a reseller and ... already negotiated its first Rhapsody sale with the Kobe Circulation Clinic, ... quality medical care. , ... Auckland, NZ (PRWEB) ...
... LLP, founded in 1968, has successfully represented victims of negligence, personal ... , ... (PRWEB) January 6, 2008 -- Smiley & ... personal injury, wrongful death and medical malpractice for over 40 years. ...
... knew there had to be a better way. He and ... how best to engage patients with chronic diseases in effective ... Chronic Care Model. More than 1,500 U.S. and international medical ... evidence on how the Model performs in practice confirms that ...
... Technology Company today announces the award of a network IP-Based ... ... Washington, D.C. (PRWEB) December 15, 2008 -- ... Notification Technology Company, today announces the award of a network ...
... and surgeon medical liability, launched its first Southeast Legal Summit ... have the most current information regarding the defense of medical ... ... California (Vocus) December 17, 2008--- The Doctors Company , ...
Cached Medicine News:Health News:TransUnion Names New Vice President of Healthcare Information Solutions 2Health News:Orion Health Signs Trinity Design for Japanese Market 2Health News:Orion Health Signs Trinity Design for Japanese Market 3Health News:Prominent New York City Personal Injury Law Firm Founded in 1968 Stays at the Cutting Edge with Launch of Video-Based Website 2Health News:Chronic Care Model helps improve people’s health and care 2Health News:Chronic Care Model helps improve people’s health and care 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 2Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 4Health News:The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians 2
The 3.0 mm Cannulated Screw can be used with or without threaded washer. Uses 1.1 mm threaded or non-threaded guide wire. , ,The Threaded Washer provides a recessed internal buttress which allows the...
... BIAX Total Wrist System was the first wrist ... normal wrist. Since then it has become the ... , ,During total wrist replacement surgery, doctors remove ... joint replacement implant in place of the damaged ...
... a simple, effective instrument to grasp soft tissue ... and loop. The grasping function of the instrument ... and precisely place a stitch up to 1 ... all in one quick step. The sterile, single ...
... Punch Forceps provide superior tissue excision with ... an aggressive tooth pattern to capture loose ... a unique stress pin buffering system to ... use, the stress pin buffering system applies ...
Medicine Products: